Navigation Links
Irvine Scientific and Selexis to Announce Results of Successful Collaboration
Date:10/12/2009

GENEVA, and SANTA ANA, Calif., Oct. 12 /PRNewswire/ -- Selexis SA ("Selexis") and Irvine Scientific Inc. ("Irvine") announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines. Irvine and Selexis will jointly present the results on Tuesday, October 13, 2009 at 11:45 AM at the BioProcess International Conference 2009 being held in Raleigh, North Carolina. Results of the program demonstrate the ability to produce gram quantities of therapeutic antibodies in 16 weeks using a CHO platform designed specifically for large scale cGMP manufacturing.

"By combining the world class media development capabilities found at Irvine Scientific with the speed and performance of the Selexis SURE Cell Line Development(TM) program a very powerful CHO based production platform has been developed," said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "This platform can be implemented for the production large qualities of antibody or recombinant protein useful for preclinical and clinical development purposes, which is beneficial to both our licensees and service clients."

"Our scientists have been able to quickly develop and apply an advanced media program to support the speed and performance of the Selexis system in achieving gram per liter productivities in matter of weeks," said Makoto Shintani, Chief Executive Officer. "It is clear that this program can provide significant benefits to biotech companies in need of large quantities of antibodies or proteins quickly."

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells - Selexis Genetic Elements(TM). Selexis has further developed platforms, to include: Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Selexis SURE Cell Line Development(TM) and Selexis INTEGRA-D2M(TM).

About Irvine Scientific:

Irvine Scientific, a subsidiary of Japan Energy Corporation, is a worldwide leader in the design, manufacture and distribution of medical devices including Industrial Cell Culture, Cytogenetic, and Assisted Reproductive Technology (ART) products. Irvine Scientific is a large scale producer of advanced and quality cell culture media for the industrial bioprocess and diagnostic markets. The company has extensive experience in the design of culture media leading to significant improvement in biopharmaceutical production yield. The company also manufactures media for medical and stem cell applications.

Irvine Scientific's worldwide distribution channels deliver products to large scale biopharmaceutical industry and to the research and laboratory communities.

    For more information contact:

    Irvine Scientific
    Phone: +949-261-7800
    Email tmrequest@irvinesci.com

    Selexis
    Phone: +41 (0)22 308 93 60
    Email: SURE@selexis.com

SOURCE Irvine Scientific Inc.


'/>"/>
SOURCE Irvine Scientific Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division
2. Irvine Scientific Announced Today a New Distribution Partnership With Prodimed
3. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
4. Irvine Scientific Launches IS CHO-CD XP(TM)
5. Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies
6. Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy
7. BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Nanogea Announces New Scientific Advisory Board Members
10. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
11. Global Public Health the Focus of Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
(Date:1/19/2017)... and HOUSTON , Jan. 19, ... today announced the formation of its Medical/Clinical Advisory ... and industry veterans who enhance the range and ... accelerates development of its novel prenatal diagnostic tests.  ... clinical and strategic guidance for the company,s product ...
(Date:1/19/2017)... and Markets ... addition of the "Implantable Biomaterials Market Analysis & ... to their offering. Report Highlights: ... current and future market trends to identify the investment opportunities ... numbers Key market trends across the business segments, Regions ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
(Date:12/22/2016)... , December 22, 2016 SuperCom ... of secure solutions for the e-Government, Public Safety, HealthCare, and Finance ... of SuperCom, has been selected to implement and deploy a community-based ... Northern California , further expanding its presence in ... This ...
Breaking Biology News(10 mins):